SCHEMBL3763129

SCHEMBL3763129

O=C(CN1CCC2(CC1)C(=O)Nc1ccccc12)N1CCN(C2CCC2)CC1

nearest known ligand 0.55

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 1/20 0.55
OPRK1 P41145 1/20 0.55
OPRL1 P41146 1/20 0.55
HTR1A P08908 8/20 0.47
HTR2A P28223 8/20 0.47
HTR7 P34969 8/20 0.47
HTR6 P50406 8/20 0.47
PARP1 P09874 2/20 0.47
KDM4E B2RXH2 3/20 0.46
ALDH1A1 P00352 2/20 0.46
CALCRL Q16602 1/20 0.45
HRH3 Q9Y5N1 2/20 0.41
MEN1 O00255 1/20 0.40
HTT P42858 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3774572 0.85 PARP1 (0.42) OPRM1OPRK1OPRL1HTR1AHTR2A
SCHEMBL3762803 0.81 OPRL1 (0.57) OPRM1OPRK1OPRL1PARP1KDM4E
SCHEMBL20066043 0.80 OPRM1 (0.46) OPRM1OPRK1OPRL1HTR1AHTR2A
SCHEMBL30179345 0.80 OPRM1 (0.46) OPRM1OPRK1OPRL1HTR1AHTR2A
SCHEMBL3767757 0.79 HRH3 (0.49) PARP1KDM4EALDH1A1HRH3MEN1
SCHEMBL23778450 0.78 OPRM1 (0.48) OPRM1OPRK1OPRL1HTR1AHTR2A
SCHEMBL3774344 0.78 EGLN1 (0.44) OPRM1OPRK1OPRL1PARP1KDM4E
SCHEMBL3770771 0.78 SIGMAR1 (0.51) OPRM1OPRL1PARP1KDM4EALDH1A1
SCHEMBL3771973 0.77 ALDH1A1 (0.46) OPRM1OPRK1OPRL1PARP1KDM4E
SCHEMBL13005817 0.77 OPRL1 (0.60) OPRM1OPRK1OPRL1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
EP-1909797-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2008-04-16 EP disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 OPRM1 743/4885OPRK1 287/4885OPRL1 347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.